Is LIMN a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Liminatus Pharma (LIMN) rests on Lead anti-CD47 program: IBA101 is positioned as a next-generation CD47-blocking monoclonal antibody, a class designed to remove the 'don't eat me' signal that tumors use to evade immune cells. The bear case rests on liminatus carries the full stack of risks that define a distressed pre-revenue biotech. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company based in Cerritos, California, focused on therapies that use the immune system to detect and attack cancer cells. Its lead candidate is IBA101, a humanized anti-CD47 monoclonal antibody intended as a next-generation immune checkpoint inhibitor, with an initial focus on advanced solid tumors including non-small cell lung cancer. The broader pipeline includes a Guanylyl Cyclase C (GCC) cancer vaccine program and, through a planned merger with InnocsAI, CAR-T and antibody candidates such as IBC101, a CD19xCD22 bivalent CAR-T cleared for an early-phase study in Korea. The company has no approved products and generates no revenue. Liminatus became a public company by merging with the special purpose acquisition company Iris Acquisition Corp and began trading on Nasdaq under the ticker LIMN on May 1, 2024. Since then it has operated under significant financial strain. For 2025 it reported zero revenue and a net loss of roughly $10.2 million, ending the year with only about $338,000 in cash and an accumulated deficit near $38.9 million, prompting management to disclose substantial doubt about its ability to continue as a going concern. A February 2026 equity and warrant financing raised roughly $3.4 million in net proceeds, lifting cash to about $1.9 million by the end of the first quarter of 2026, when the accumulated deficit reached about $40.0 million. The company received multiple Nasdaq deficiency notices over minimum bid price and market value requirements during late 2025 and 2026, and in May 2026 it received a delisting determination, which it appealed to a Nasdaq Hearings Panel, automatically staying any suspension while the appeal is pending.
The bull case for LIMN
1. Lead anti-CD47 program.
IBA101 is positioned as a next-generation CD47-blocking monoclonal antibody, a class designed to remove the 'don't eat me' signal that tumors use to evade immune cells. The company has announced plans to initiate a Phase 1 trial in advanced solid tumors, including non-small cell lung cancer. Positive early safety and signal data would be the main catalyst for the stock. CD47 is a well-studied but historically difficult target where several larger programs have struggled.
2. Pipeline breadth and the InnocsAI merger.
Beyond IBA101, Liminatus has described a Guanylyl Cyclase C cancer vaccine program and a planned acquisition of InnocsAI that would add CAR-T and antibody candidates, including a CD19xCD22 bivalent CAR-T cleared for an early-phase study in Korea. A wider pipeline spreads the bet across more shots on goal. It also adds complexity, integration risk, and likely large share issuance to fund and complete the deal.
3. Financing is the immediate driver.
With cash measured in low single-digit millions and a going concern warning, Liminatus depends on continued capital raises to operate. The February 2026 equity and warrant financing kept the lights on but was small. Each raise tends to come at depressed prices and dilutes existing holders, so the timing, size, and terms of the next financing matter more to the share price right now than any clinical readout.
4. Nasdaq listing as a binary overhang.
The company has received deficiency notices on minimum bid price and market value rules and a formal delisting determination, which it is appealing before a Nasdaq Hearings Panel. The appeal stays any suspension while it is heard. Regaining compliance, potentially through a reverse split or a higher market value, would remove a major overhang, while an unfavorable outcome could push the stock to over-the-counter markets and sharply reduce liquidity.
The bear case for LIMN
Liminatus carries the full stack of risks that define a distressed pre-revenue biotech. It has no products and no revenue, an accumulated deficit near $40 million, and management has disclosed substantial doubt about its ability to continue as a going concern, meaning it may be unable to fund operations without raising more capital on potentially harsh terms. Its lead asset, IBA101, is still early and unproven, and CD47 is a target where larger, better-funded programs have repeatedly failed, so a single clinical setback could be decisive given how concentrated the value is in a handful of early programs. The company faces an active Nasdaq delisting process, and continued financings, plus the share issuance tied to the proposed InnocsAI merger, point to heavy dilution. The stock trades as a sub-dollar micro-cap with low liquidity and high volatility, and a total loss is a realistic outcome.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding LIMN already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on LIMN
Too few analysts publish on LIMN for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The LIMN forecast page covers what coverage does exist.
How is LIMN valued? (as of FY2025 (10-K) and Q1 2026 (quarter ended March 31, 2026))
Snapshot for LIMN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue: $0 (no approved products)
- Net loss (FY2025): ~$10.2 million
- Net loss (Q1 2026): ~$1.1 million
- Cash: ~$1.9 million (Mar 31, 2026)
- Accumulated deficit: ~$40.0 million
- Market cap: ~$5-6 million (mid-2026, sub-$1 share)
For a clinical-stage biotech with no revenue, traditional metrics like P/E or price-to-sales do not apply, so the numbers that matter are cash on hand, the quarterly cash burn, and the runway between them. Here the runway is very short: a roughly $1 million quarterly loss against under $2 million in cash means the company must keep raising money to operate, which is why management disclosed going concern doubt. Read the market cap as the market's small, heavily discounted estimate of a binary pipeline rather than a multiple of any earnings, and treat each financing and clinical update as the real value driver.
How do you decide if LIMN is a buy?
Rather than asking whether LIMN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold LIMN indirectly through an index or sector ETF before adding more.
What would change your mind on LIMN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Lead anti-CD47 program stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: liminatus carries the full stack of risks that define a distressed pre-revenue biotech fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the LIMN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about LIMN against your real portfolio and see your actual exposure before deciding.
Investing in Liminatus Pharma with AI
Connect the broker you already use and ask Walnut's AI how LIMN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is LIMN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Lead anti-CD47 program, with revenue at $0 (no approved products). The bear case rests on liminatus carries the full stack of risks that define a distressed pre-revenue biotech. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell LIMN?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Liminatus carries the full stack of risks that define a distressed pre-revenue biotech. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.
What is the bull case for LIMN?
+
Lead anti-CD47 program. IBA101 is positioned as a next-generation CD47-blocking monoclonal antibody, a class designed to remove the 'don't eat me' signal that tumors use to evade immune cells.
What is the bear case for LIMN?
+
Liminatus carries the full stack of risks that define a distressed pre-revenue biotech. It has no products and no revenue, an accumulated deficit near $40 million, and management has disclosed substantial doubt about its ability to continue as a going concern, meaning it may be unable to fund operations without raising more capital on potentially harsh terms. Its lead asset, IBA101, is still early and unproven, and CD47 is a target where larger, better-funded programs have repeatedly failed, so a single clinical setback could be decisive given how concentrated the value is in a handful of early programs. The company faces an active Nasdaq delisting process, and continued financings, plus the share issuance tied to the proposed InnocsAI merger, point to heavy dilution. The stock trades as a sub-dollar micro-cap with low liquidity and high volatility, and a total loss is a realistic outcome.
What does Liminatus Pharma do?
+
A distressed, clinical-stage immuno-oncology micro-cap developing the anti-CD47 antibody IBA101 and other cancer immunotherapies, facing going-concern doubt and a Nasdaq delisting appeal.
What would have to change for LIMN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Lead anti-CD47 program) stalling in the reported numbers rather than in the narrative, the risk above (liminatus carries the full stack of risks that define a distressed pre-revenue biotech) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Liminatus Pharma do?
+
Liminatus Pharma is a clinical-stage immuno-oncology company developing therapies that use the immune system to fight cancer. Its lead candidate, IBA101, is a next-generation anti-CD47 monoclonal antibody planned for a Phase 1 trial in advanced solid tumors, and its broader pipeline includes a GCC cancer vaccine and, via a proposed merger, CAR-T programs. It has no approved products and no revenue.
Does LIMN pay a dividend?
+
No. Liminatus Pharma does not pay a dividend. It is a pre-revenue clinical-stage biotech that is burning cash on research and operations and has disclosed going concern doubt, so any available capital goes toward funding the business rather than shareholder payouts. Investors in this kind of company are betting on future clinical progress, not income.
Why did LIMN get a Nasdaq delisting notice?
+
Liminatus received Nasdaq deficiency notices in late 2025 and 2026 for failing minimum bid price and market value requirements, and in May 2026 it received a formal delisting determination. The company appealed to a Nasdaq Hearings Panel, which automatically stays any suspension while the appeal is heard. The outcome is a significant overhang on the stock.
Walnut is informational, not investment advice, and gives no verdict on LIMN. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.